- Home
- Protocols
-
Ask a
question
The FINGER trial protocol, baseline population characteristics, and primary results have been previously described in detail. The present study is a prespecified subgroup analysis by APOE genotype. Participants were recruited at 6 study sites across Finland from previous population-based observational studies. Eligibility criteria were age of 60 to 77 years; Cardiovascular Risk Factors, Aging, and Dementia risk score of 6 points or higher; the Consortium to Establish a Registry for Alzheimer Disease word list memory task (10 words 3 times) score of 19 words or fewer; Consortium to Establish a Registry for Alzheimer Disease word list recall of 75% or less; or Mini-Mental State Examination score of 26 or fewer of 30 points. Exclusion criteria were previously diagnosed dementia, suspected dementia after clinical assessment by a study physician at the screening visit (individuals recommended for further investigations), Mini-Mental State Examination score of less than 20 points, and conditions that affect safe engagement in the intervention (eg, malignant tumor; major depression; symptomatic cardiovascular disease; revascularization within 1 year); severe vision, hearing, or communicative impairment; conditions that prevent cooperation as judged by the study physician; and coincident participation in another trial. FINGER and this subgroup analysis were approved by the Coordinating Ethics Committee of the Hospital District of Helsinki and Uusimaa. Participants gave written informed consent at screening and baseline visits. All data were deidentified.
Do you have any questions about this protocol?
Post your question to gather feedback from the community. We will also invite the authors of this article to respond.
Post a Question
